https://charts.traderzeitung.de/phases/US52886X1072 string(1420) "{"isin":"US52886X1072","name":"Lexeo Therapeutics Inc","stock_id_xnas":35731811,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.07,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":4.25,"close_at":"2026-09-22 15:07:00","complete":true,"perf_pct":4.4226},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.07,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-4.2353},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.525,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-13.3907},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Lexeo Therapeutics Aktie News & Nachrichten

[WKN: A3EXD2 | Symbol: LXEO]

Realtimekurs

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Lexeo Therapeutics gefunden werden.

Lexeo Therapeutics Nachrichtenticker öffnen

MT Newswires 22.09.2026 14:13 Uhr

Lexeo Therapeutics übernimmt Mantle Therapeutics für bis zu 21,3 Millionen US-Dollar und geht drei Forschungskooperationen ein

08:12 AM EDT, 22.09.2026 (MT Newswires) -- Lexeo Therapeutics (LXEO) hat sich bereit erklärt, Mantle Therapeutics für bis zu 21,3 Millionen US-Dollar

MT Newswires 15.06.2026 15:30 Uhr

Lexeo Therapeutics finalisiert Studiendesign für Friedreich-Ataxie-Gentherapie

09:29 AM EDT, 06/15/2026 (MT Newswires) -- Lexeo Therapeutics (LXEO) hat ein entscheidendes Studiendesign zur Evaluierung des Gentherapie-Kandidaten L